TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Enorama Pharma AB
Closing information (x1000 DKK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
10,241
|
912
|
4,575 |
| Financial expenses |
1,942
|
2,411
|
1,395 |
| Earnings before taxes |
-28,450
|
-29,965
|
-28,086 |
| EBITDA |
-17,604
|
-25,913
|
-25,348 |
| Total assets |
10,322
|
23,096
|
32,557 |
| Current assets |
9,846
|
8,708
|
7,853 |
| Current liabilities |
5,255
|
6,863
|
8,303 |
| Equity capital |
5,068
|
13,123
|
21,065 |
| - share capital |
6,137
|
4,295
|
976 |
| Employees (average) |
5
|
5
|
9 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
49.1%
|
56.8%
|
64.7% |
| Turnover per employee |
2,048
|
182
|
508 |
| Profit as a percentage of turnover |
-277.8%
|
-3285.6%
|
-613.9% |
| Return on assets (ROA) |
-256.8%
|
-119.3%
|
-82.0% |
| Current ratio |
187.4%
|
126.9%
|
94.6% |
| Return on equity (ROE) |
-561.4%
|
-228.3%
|
-133.3% |
| Change turnover |
9,359
|
-3,687
|
-2,799 |
| Change turnover % |
1061%
|
-80%
|
-38% |
| Chg. No. of employees |
0
|
-4
|
-1 |
| Chg. No. of employees % |
0%
|
-44%
|
-10% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.